Publications
Detailed Information
Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Song, Jin Su | - |
dc.contributor.author | Kim, Nak-Hyun | - |
dc.contributor.author | Park, Sang Won | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.contributor.author | Kim, Hong Bin | - |
dc.contributor.author | Song, Kyoung-Ho | - |
dc.date.accessioned | 2012-06-27T05:05:20Z | - |
dc.date.available | 2012-06-27T05:05:20Z | - |
dc.date.issued | 2010-10 | - |
dc.identifier.citation | JOURNAL OF KOREAN MEDICAL SCIENCE; Vol.25 10; 1427-1430 | ko_KR |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77567 | - |
dc.description.abstract | Hyperbilirubinemia is frequently observed in Caucasian HIV patients treated with atazanavir. UDP-glucuronosyltransferase 1A1 polymorphism, UGT1A1*28, which is associated with atazanavir-induced hyperbilirubinemia, is less common in Asians than in Caucasians. However, little is known about the incidence of atazanavir-associated hyperbilirubinemia in Asian populations. Our objective was to investigate the incidence of and tolerability of atazanavir-associated hyperbilirubinemia in Korean HIV patients. The prevalence and cumulative incidence of atazanavir-associated hyperbilirubinemia and UGT1A1*28 allele frequency was investigated in 190 Korean HIV-infected patients treated with atazanavir 400 mg per day. The UGT1A1*28 were examined by direct sequencing of DNA from peripheral whole blood. The UGT1A1*28 allele frequency was 11%. The cumulative incidence of any grade of hyperbilirubinemia was 77%, 89%, 98%, and 100%, at 3, 12, 24, and 30 months, respectively. The cumulative incidence of severe (grade 3-4) hyperbilirubinemia was 21%, 41%, 66%, and 75%, at 3, 12, 24, and 30 months, respectively. However, the point prevalence of severe hyperbilirubinemia did not increase with time and remained around 25%. Our data suggest that atazanavir-associated hyperbilirubinemia is common but transient in a population with low UGT1A1*28 allele frequency. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | ko_KR |
dc.subject | HIV | ko_KR |
dc.subject | Acquired Immunodeficiency Syndrome | ko_KR |
dc.subject | Jaundice | ko_KR |
dc.subject | Hyperbilirubinemia | ko_KR |
dc.subject | Atazanavir | ko_KR |
dc.title | Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 최평균 | - |
dc.contributor.AlternativeAuthor | 박완범 | - |
dc.contributor.AlternativeAuthor | 송진수 | - |
dc.contributor.AlternativeAuthor | 김낙현 | - |
dc.contributor.AlternativeAuthor | 송경호 | - |
dc.contributor.AlternativeAuthor | 박상원 | - |
dc.contributor.AlternativeAuthor | 김홍빈 | - |
dc.contributor.AlternativeAuthor | 김남중 | - |
dc.contributor.AlternativeAuthor | 오명돈 | - |
dc.identifier.doi | 10.3346/jkms.2010.25.10.1427 | - |
dc.citation.journaltitle | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.description.citedreference | Choi H, 2008, J KOREAN MED SCI, V23, P737, DOI 10.3346/jkms.2008.23.4.737 | - |
dc.description.citedreference | Rodriguez-Novoa S, 2007, AIDS, V21, P41 | - |
dc.description.citedreference | KIM JO, 2007, GENOMICS INFORM, V5, P161 | - |
dc.description.citedreference | Johnson M, 2006, AIDS, V20, P711 | - |
dc.description.citedreference | Rotger M, 2005, J INFECT DIS, V192, P1381 | - |
dc.description.citedreference | Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99 | - |
dc.description.citedreference | Takeuchi K, 2004, J GASTROEN HEPATOL, V19, P1023, DOI 10.1111/j.1400-1746.2004.03370.x | - |
dc.description.citedreference | Squires K, 2004, JAIDS-J ACQ IMM DEF, V36, P1011 | - |
dc.description.citedreference | Wood R, 2004, JAIDS-J ACQ IMM DEF, V36, P684 | - |
dc.description.citedreference | Havlir DV, 2004, CLIN INFECT DIS, V38, P1599 | - |
dc.description.citedreference | Ki CS, 2003, CLIN CHEM, V49, P2078, DOI 10.1373/clinchem.2003.024174 | - |
dc.description.citedreference | Zucker SD, 2001, P NATL ACAD SCI USA, V98, P12671 | - |
dc.description.citedreference | Fellay J, 2001, LANCET, V358, P1322 | - |
dc.description.citedreference | Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170 | - |
dc.description.citedreference | BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.